^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Cutaneous Melanoma

Related cancers:
21h
Assessing the use of anti-PD1 monotherapy as adjuvant therapy and determinants of treatment choice in stage III cutaneous melanoma in the US. (PubMed, BMC Cancer)
Most patients were given AT with a vast majority treated with an anti-PD1 therapy. Physician- and patient-level evidence confirmed the impact of disease substage on AT use, with stage IIIA patients, patients without adequate insurance coverage, and worse ECOG status having a lower probability of receiving AT.
Journal
|
BRAF (B-raf proto-oncogene)
1d
Evaluation of the association between glutathione S-transferase polymorphisms and susceptibility to cutaneous melanoma: a systematic review and meta-analysis. (PubMed, Postepy Dermatol Alergol)
The current evidence is not sufficient to confirm or reject the intervention effect. Future research should consider gene-gene and gene-environment interactions, which could offer a more comprehensive understanding of the complex biology of melanoma.
Retrospective data • Review • Journal
|
GSTP1 (Glutathione S-transferase pi 1) • GSTM1 (Glutathione S-transferase mu 1) • GSTT1 (Glutathione S-transferase theta 1)
2d
NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma (clinicaltrials.gov)
P1, N=30, Recruiting, Dana-Farber Cancer Institute | N=20 --> 30
Enrollment change • Combination therapy
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Mobista (CDX-301) • Neo Vax (NEO-PV-01)
2d
NCI-2018-01928: CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma (clinicaltrials.gov)
P1, N=7, Terminated, Roswell Park Cancer Institute | N=36 --> 7 | Trial completion date: Aug 2024 --> Jan 2024 | Recruiting --> Terminated | Trial primary completion date: Aug 2024 --> Jan 2024; low accrual
Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
4d
Density of high endothelial venules and PDL-1 expression: relationship with tumor-infiltrating lymphocytes in primary cutaneous melanomas. (PubMed, An Acad Bras Cienc)
Our findings confirm the HEV role in the recruitment and facilitation of lymphocyte transport in cutaneous melanomas, where HEV density is strongly associated with the degree of TILs. Additionally, PDL-1 hyperexpression suggests a possible mechanism of tumor immune evasion, which may lead to inactivation and reduction of the tumor lymphocytes number.
Journal • Tumor-infiltrating lymphocyte • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
5d
The health economic impact of the 31-gene expression profile test for treatment and surveillance management plans in patients with cutaneous melanoma (EADO 2024)
Importantly, >90% of savings occurred during the first year post-diagnosis. Conclusions For patients with stage I-IIIA CM, 31-GEP-guided clinical management decisions result in substantial cost savings, especially in the first year, for commercial payors compared to AJCC-guided care.
Clinical • HEOR • Gene Expression Profile • Gene expression profiling
|
DecisionDx®-Melanoma
5d
Patients who forego sentinel lymph node biopsy after 31-GEP testing are not harmed: A prospective, multicenter analysis (EADO 2024)
The 31-GEP identified patients at low risk of SLN positivity who may safely forego SLNB, reducing healthcare costs and procedure complications. Longer follow-up may be needed to further validate this conclusion
Clinical • Biopsy
|
DecisionDx®-Melanoma
5d
Gene Signatures predict immune-related skin adverse events in melanoma patients (EADO 2024)
Methods Gene profiling analysis was performed using NanoString IO360 panel from PBMCs of pts with cutaneous melanoma treated with antiPD1 (pembrolizumab or nivolumab) in both clinical setting (adjuvant and first line therapy). Conclusions In this retrospective study, we identify gene signatures model associated with the onset of skin toxicities related to anti-PD1 treatment in stage III/IV unresectable and resected stage III melanoma pts. Further investigations are needed in order to validate the signature in an independent dataset.
Clinical • Adverse events • Gene Signature • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • ER (Estrogen receptor) • TNFRSF8 (TNF Receptor Superfamily Member 8) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • CXCR3 (C-X-C Motif Chemokine Receptor 3) • ADAM12 (ADAM Metallopeptidase Domain 12) • DUSP5 (Dual Specificity Phosphatase 5) • ITGA1 (Integrin Subunit Alpha 1)
|
nCounter® PanCancer IO 360™ Panel
|
Keytruda (pembrolizumab) • Opdivo (nivolumab)
7d
Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies (clinicaltrials.gov)
P1, N=35, Completed, Rahul Aggarwal | Active, not recruiting --> Completed | Phase classification: P1b --> P1
Trial completion • Phase classification • Combination therapy • Metastases
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
Keytruda (pembrolizumab) • abexinostat (CG-781)
7d
Role of hippo pathway and cuproptosis-related genes in immune infiltration and prognosis of skin cutaneous melanoma. (PubMed, Front Pharmacol)
In conclusion, the present study demonstrated the prognostic value of Hippo pathway-related genes (particularly YAP1) in melanoma, revealing the correlation between the expression of Hippo pathway-related genes and immune infiltration. Thus, the present findings may provide new clues on the prognostic assessment of patients with melanoma and a new target for the immunotherapy of this disease.
Journal • IO biomarker
|
YAP1 (Yes associated protein 1) • FDX1 (Ferredoxin 1)
8d
Ipilimumab and Imatinib Mesylate in Advanced Cancer (clinicaltrials.gov)
P1, N=68, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed
Trial completion • Metastases
|
KIT (KIT proto-oncogene, receptor tyrosine kinase)
|
KIT mutation • KIT positive
|
Yervoy (ipilimumab) • imatinib
8d
Trial suspension • Combination therapy
|
BRAF (B-raf proto-oncogene)
|
Keytruda (pembrolizumab) • vidutolimod (CMP-001)
9d
Identification of patients at high risk for relapse by Merlin Assay (CP-GEP) in an independent cohort of patients with melanoma who did not undergo sentinel lymph node biopsy: head and neck subgroup analysis (EADO 2024)
Pts with CP-GEP Low-Risk have a good long-term survival compared to pts with High-Risk, even though SLN status was not assessed. This also seems true for patients with H&N melanoma, which may allow clinicians to skip SLNB in this difficult anatomic localization.
Clinical • Biopsy
|
CXCL8 (Chemokine (C-X-C motif) ligand 8) • GDF15 (Growth differentiation factor 15) • MLANA (Melan-A) • TGFBR1 (Transforming Growth Factor Beta Receptor 1) • ITGB3 (Integrin Subunit Beta 3)
|
Merlin Assay
10d
Methylation‑sensitive restriction enzyme‑droplet digital PCR assay for the one‑step highly sensitive analysis of DNA methylation hotspots. (PubMed, Int J Mol Med)
Compared with the standard MSRE approaches, the MSRE‑ddPCR assay is more appropriate for the analysis of DNA methylation (methDNA) in samples with low amounts of DNA (up to 0.651 ng) showing a greater sensitivity. These findings suggested the potential clinical application of MSRE‑ddPCR paving the way to the analysis of other methDNA hotspots in different tumors.
Journal • Epigenetic controller
|
SLC22A3 (Solute Carrier Family 22 Member 3)
10d
New P2 trial
|
Opdualag (nivolumab/relatlimab)
11d
ALKBH5 facilitates the progression of skin cutaneous melanoma via mediating ABCA1 demethylation and modulating autophagy in an m6A-dependent manner. (PubMed, Int J Biol Sci)
Finally, our data demonstrated that ALKBH5 promoted SKCM via mediating ABCA1 downregulation by reducing ABCA1 mRNA stability in an m6A-dependent manner. Our findings exhibited the functional value of the key demethylase ALKBH5 mediated m6A modification in the progression of SKCM, suggesting the ALKBH5-m6A-ABCA1 axis as a potential therapeutic target in SKCM.
Journal
|
ABCA1 (ATP Binding Cassette Subfamily A Member 1) • ALKBH5 (AlkB Homolog 5, RNA Demethylase)
11d
Enrollment change • Surgery • Post-surgery
|
CD4 (CD4 Molecule)
|
CDKN2A negative
|
Keytruda (pembrolizumab) • IO102-IO103
11d
18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases (clinicaltrials.gov)
P1, N=10, Active, not recruiting, University of Southern California | Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: Feb 2024 --> Feb 2025
Trial completion date • Trial primary completion date
12d
TNFRSF1B Gene Variants in Clinicopathological Aspects and Prognosis of Patients with Cutaneous Melanoma. (PubMed, Int J Mol Sci)
miR-1271 had less efficient binding with the 3'-UTR of the T allele when compared with the C allele of the SNV c.*922C>T. Our findings, for the first time, demonstrate that TNFRSF1B c.587T>G and c.*922C>T variants can serve as independent prognostic factors in CM patients.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • MIR96 (MicroRNA 96) • MIR127 (MicroRNA 127) • MIR1271 (MicroRNA 1271) • TNFRSF1B (TNF Receptor Superfamily Member 1B)
13d
Inhibiting IL11RA to mitigate hepatic metastasis in skin cutaneous melanoma: Comprehensive insights from in vitro and in vivo investigations. (PubMed, Skin Res Technol)
IL11RA plays a crucial role in SKCM metastasis, affecting migratory and invasive abilities. Targeting IL11RA may offer a promising avenue for therapeutic interventions in cutaneous melanoma progression.
Preclinical • Journal
|
MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9) • IL1R1 (Interleukin 1 receptor, type I) • MMP8 (Matrix Metallopeptidase 8)
14d
Enrollment open
|
ABP 206 (nivolumab biosimilar) • nivolumab subcutaneous (BMS-986298)
14d
Comprehensive Pan-cancer Analysis of CMPK2 as Biomarker and Prognostic Indicator for Immunotherapy. (PubMed, Curr Cancer Drug Targets)
Our analysis preliminarily describes the complex function of CMPK2 in cancer progression and immune microenvironment highlighting its potential as a diagnostic and therapeutic target for immunotherapy.
Journal • IO biomarker • Pan tumor
|
NLRP3 (NLR Family Pyrin Domain Containing 3)
14d
Pembrolizumab/Lenvatinib With and Without Responder-derived FMT in Relapsed/Refractory Melanoma (clinicaltrials.gov)
P2, N=56, Not yet recruiting, Diwakar Davar | Trial completion date: Dec 2028 --> Jun 2029 | Initiation date: Jan 2024 --> May 2024 | Trial primary completion date: Dec 2026 --> Jun 2029
Trial completion date • Trial initiation date • Trial primary completion date
|
Keytruda (pembrolizumab) • Lenvima (lenvatinib)
15d
Comprehensive analysis of the effects of the cuprotosis-associated gene SLC31A1 on patient prognosis and tumor microenvironment in human cancer. (PubMed, Transl Cancer Res)
The RT-qPCR and WB results were consistent with the predicted results. SLC31A1 may be a potential target related to cancer energy metabolism and may have prognostic value.
Journal • Tumor mutational burden • BRCA Biomarker
|
TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • BRCA (Breast cancer early onset) • SLC31A1 (Solute Carrier Family 31 Member 1)
16d
Tumor-infiltrating macrophage associated lncRNA signature in cutaneous melanoma: implications for diagnosis, prognosis, and immunotherapy. (PubMed, Aging (Albany NY))
In addition, the signature was associated with different immune microenvironment and applied to predict response of immune checkpoint inhibitor therapy (low risk of patients well respond to anti-PD-1 therapy and high risk is insensitive to anti-CTLA-4 therapy). Therefore, our finding supplies a more accuracy and effective lncRNA signature for tumor-infiltrating macrophages targeting treatment approaches and affords a new clinical application for predicting the response of immunotherapies in melanomas.
Journal • PD(L)-1 Biomarker • IO biomarker
|
LINC00518 (Long Intergenic Non-Protein Coding RNA 518) • LINC02910 (Long Intergenic Non-Protein Coding RNA 2910)
16d
MCL1 inhibition targets Myeloid Derived Suppressors Cells, promotes antitumor immunity and enhances the efficacy of immune checkpoint blockade. (PubMed, Cell Death Dis)
In this study, we show that the MCL1 inhibitor S64315 reduces melanoma tumor growth in an immune cell-dependent manner in mice...Together, this proof-of-concept study demonstrates the potential of combining an MCL1 inhibitor with anti-PD-1 in the treatment of melanoma. It justifies the further development of next generation MCL1 inhibitors to improve efficacy of ICIs in treating malignant melanoma.
Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker • Checkpoint block
|
BCL2 (B-cell CLL/lymphoma 2) • CD8 (cluster of differentiation 8)
|
MCL1 expression
|
MIK665
16d
Targeted DNA Methylation Editing Using an All-in-One System Establishes Paradoxical Activation of EBF3. (PubMed, Cancers (Basel))
Further, our study provides novel insights into the function of the EBF3 gene, which remains largely unknown. Overall, this study challenges the conventional view of methylation as solely a gene-silencing mechanism and demonstrates a potential function of EBF3 in IFN pathway signalling, potentially uncovering new insights into epigenetic drivers of malignancy and metastasis.
Journal • Epigenetic controller
|
EBF3 (EBF Transcription Factor 3)
16d
Trial completion date
|
CASP3 (Caspase 3)
|
Koselugo (selumetinib) • Recentin (cediranib)
16d
Trial completion date • Metastases
|
MK-2206 • hydroxychloroquine
17d
Multidisciplinary approach and treatment of acral and mucosal melanoma. (PubMed, Front Oncol)
This divergence in mutational patterns may partially account for the relatively poorer prognosis, particularly to immune checkpoint inhibitors. This review explores various aspects of acral and mucosal melanoma, including their clinical presentation, pathologic features, mutational profiles, current therapeutic approaches, outcomes associated with systemic therapy, and potential strategies to address resistance to existing treatments.
Review • Journal • IO biomarker
|
KIT (KIT proto-oncogene, receptor tyrosine kinase)
|
KIT mutation
17d
Expression and prognostic role of sphingosine 1-phosphate receptor 4 (S1PR4) as a biomarker of skin cutaneous melanoma. (PubMed, Heliyon)
Patients in the high-expression group had significantly longer disease survival and progression-free survival than those in the low-expression group. High S1PR4 expression was highly associated with better prognosis and milder clinical manifestations; thus, S1PR4 may be used as a prognostic marker to help physicians monitor patients with SKCM.
Journal
|
S1PR1 (Sphingosine-1-Phosphate Receptor 1)
17d
Amplification of mutant NRAS in melanocytic tumors with features of Spitz tumors. (PubMed, Mod Pathol)
Follow-up data were available for five patients, with a median period of 4.2 years (ranging from 1 to 9 years), during which no recurrences or metastases were reported. Our series highlights a clinicopathologically and molecularly distinctive subset of NRAS-mutated tumors with amplification of the mutant NRAS allele.
Journal
|
NRAS (Neuroblastoma RAS viral oncogene homolog)
|
NRAS mutation • NRAS amplification
18d
CDCA8, a mitosis-related gene, as a prospective pan-cancer biomarker: implications for survival prognosis and oncogenic immunology. (PubMed, Am J Transl Res)
This study provides concise insights into CDCA8's multifaceted role in KIRC, LUAD, and SKCM, covering expression patterns, diagnostic and prognostic relevance, epigenetic regulation, mutational landscape, immune infiltration, and therapeutic implications.
Journal • Pan tumor
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • CDCA8 (Cell Division Cycle Associated 8)
19d
Integrative analysis of RNA-sequencing and microarray for the identification of adverse effects of UVB exposure on human skin. (PubMed, Front Public Health)
Our findings will aid the understanding of UVB-induced cutaneous toxicity and the accompanying molecular mechanisms. In addition, the three candidate biomarkers that change molecular signals due to UVB exposure of skin might be related to the survival rate of patients with cutaneous melanoma.
Journal • Adverse events
|
CCL2 (Chemokine (C-C motif) ligand 2) • IL1B (Interleukin 1, beta)
19d
Transcriptome and single-cell transcriptomics reveal prognostic value and potential mechanism of anoikis in skin cutaneous melanoma. (PubMed, Discov Oncol)
In conclusion, we have established a novel classification system for SKCM based on anoikis, which carries substantial clinical implications for SKCM patients. Notably, the elevated expression of the FASLG gene on cluster 1 of Tex cells could significantly impact SKCM prognosis through anoikis, thus offering a promising target for the development of immunotherapy for SKCM.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • FASLG (Fas ligand) • IGF1 (Insulin-like growth factor 1) • PIK3R2 (Phosphoinositide-3-Kinase Regulatory Subunit 2 )
21d
Lymphatic expression of the proliferation marker Ki67 is linked to sentinel node positivity, recurrence and mortality in primary cutaneous melanoma. (PubMed, Exp Dermatol)
CD31+ /Ki67+ co-expression was not prognostic in this cohort. Lymphatic proliferation, as measured through D2-40+ /Ki67+ co-expression, predicted greater melanoma-specific mortality and recurrence in this cohort of primary cutaneous melanoma.
Retrospective data • Journal
|
CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
|
CD31 expression
21d
Cryptotanshinone inhibits PFK-mediated aerobic glycolysis by activating AMPK pathway leading to blockade of cutaneous melanoma. (PubMed, Chin Med)
CPT activated AMPK and then inhibited PFK-mediated aerobic glycolysis leading to inhibition of growth of cutaneous melanoma. CPT should be a promising anti-melanoma agent for clinical melanoma therapy.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit)
|
HIF1A expression • AMPK expression
22d
NCI-2021-11063: Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients (clinicaltrials.gov)
P1, N=2, Active, not recruiting, Richard Wu | Recruiting --> Active, not recruiting | N=15 --> 2 | Trial completion date: Dec 2025 --> Dec 2024
Enrollment closed • Enrollment change • Trial completion date • Tumor mutational burden • Metastases
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600 • BRAF V600K
|
Keytruda (pembrolizumab) • cyclophosphamide • fludarabine IV • Amtagvi (lifileucel)
22d
Trial completion date
|
ER (Estrogen receptor) • AFP (Alpha-fetoprotein)
|
Istodax (romidepsin)
24d
LncRNA JPX promotes tumor progression by interacting with and destabilizing YTHDF2 in cutaneous melanoma. (PubMed, Mol Cancer Res)
Overall, our study revealed a novel effect of JPX on YTHDF2 ubiquitination, suggesting the possibility of blocking the JPX/USP10/YTHDF2/BMP2 axis as a prospective therapeutic approach for cutaneous melanoma. Implications: This study highlights the ubiquitination effect of USP10 and JPX on YTHDF2 in cutaneous melanoma, and proposes that the JPX/USP10/YTHDF2/BMP2 axis may be a prospective therapeutic target for cutaneous melanoma.
Journal
|
XIST (X Inactive Specific Transcript) • YTHDF2 (YTH N6-Methyladenosine RNA Binding Protein 2) • BMP2 (Bone Morphogenetic Protein 2)
24d
Trial completion date • Metastases
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600 • BRAF V600K
|
Zelboraf (vemurafenib) • Mektovi (binimetinib) • Braftovi (encorafenib)
27d
Trial primary completion date • Metastases
|
cyclophosphamide • fludarabine IV • Amtagvi (lifileucel) • Imunace (teceleukin)